An HER1–3-neutralizing Ab mixture exerts a high antitumor activity against drug-resistant HER2-overexpressing breast cancers, suggesting that the multi-targeted Ab mixture represents a novel approach for effective treatment of breast cancers with HER2-overexpressing tumors [97]. Here, EGFR is linked to breast carcinoma.